30
Participants
Start Date
February 28, 2023
Primary Completion Date
March 31, 2027
Study Completion Date
March 31, 2027
Surgical Resection
Resection of Primary Hepatocellular Cancer Tumour.
Adjuvant Atezolizumab-Bevacizumab Therapy
Patient receives adjuvant Atezolizumab plus Bevacizumab every 3-weekly for two years following resection of hepatocellular carcinoma tumour.
RECRUITING
National University Hospital Singapore, Singapore
RECRUITING
National Cancer Centre Singapore, Singapore
RECRUITING
Singapore General Hospital, Singapore
ACTIVE_NOT_RECRUITING
Tan Tock Seng Hospital, Singapore
RECRUITING
Changi General Hospital, Singapore
RECRUITING
Sengkang General Hospital, Singapore
Singapore General Hospital
OTHER
National University Hospital, Singapore
OTHER
Changi General Hospital
OTHER
Sengkang General Hospital
OTHER
Tan Tock Seng Hospital
OTHER
Singapore Clinical Research Institute
OTHER
Genome Institute of Singapore
OTHER
Institute of Molecular and Cell Biology of Singapore
UNKNOWN
Cancer Science Institute of Singapore
UNKNOWN
Duke-NUS Graduate Medical School
OTHER
Singapore Phenome Centre
UNKNOWN
Nanyang Technological University
OTHER
NMRC OF-LCG (OFLCG21Jun-0016)
UNKNOWN
National Cancer Centre, Singapore
OTHER